Five Essential Elements to Evaluate Before Selecting a Preclinical CRO

From early discovery to clinical trials, a drug development company needs 3-5 years to bring a new molecular entity to market. Budgets are always tight, and regulatory requirements are strict. To cope, biopharma businesses outsource up to 50% of preclinical work to specialized CROs.

The choice of CRO to work with is one of the most vital decisions for biotech companies. By collaborating with a specialized preclinical UK CRO, researchers can smoothly proceed from in vitro assays to in vivo efficacy studies, avoiding regulatory problems.

1.    Specialized Knowledge and Disease Model Validation

A generalist CRO doesn’t necessarily have the necessary insight regarding complex therapeutic areas. On the other hand, a specialized CRO provides validated disease models that can provide predictive data for the team before entering clinical trials.

Find out what experience your potential CRO has in these key areas:

• Neuroscience/CNS Disorders: High-level expertise in blood-brain barrier penetration and microdialysis.
• Oncology/Respiratory Diseases: In vivo efficacy models that replicate human disease development.
• Complex DMPK: Comprehensive drug metabolism and pharmacokinetics study for small molecules and biologics.

Validated disease models will help you get accurate translational data that accurately predicts how drugs behave in humans.

2.    Stringent Regulatory Compliance and Quality Assurance

Data integrity is mandatory when creating Investigational New Drug applications. One data point in error in a regulatory filing can delay clinical trials for months and cost hundreds of thousands of pounds.

Your CRO should work strictly according to quality assurance and regulatory compliance standards:

• Regulatory-Compliant GLP and GCP: Platforms should be fully compliant with Good Laboratory Practice regulations in case of safety and toxicology studies.
• Ethical Treatment of Animals: Certification from reputable organizations like AAALAC assures application of the 3Rs (Replace, Reduce, Refine) strategy.
• Regulatory Preparedness for Global Markets: Packaging should satisfy all the stringent requirements of MHRA, FDA, and EMA.

Working with an audited CRO provides full regulatory compliance and data integrity on every occasion.

3.    High-Resolution Bioanalytical and Translational Technology Platforms

Advanced preclinical drug discovery requires advanced equipment to study complex biological interactions. Developing such platforms internally is expensive and requires maintenance costs.

Access to the existing preclinical UK CRO allows biopharmaceutical companies to utilize the latest technology platforms such as high-resolution mass spectrometry, flow cytometry, and high-throughput screening platforms instantly.

The following are some of the critical bioanalytical capabilities:

• In Vitro ADMET Screening: Fast screening of metabolic stability, toxicological problems, and drug interactions.
• Target Tissue Distribution: Capability to measure drug levels in the target tissue using advanced sampling methods.
• Biomarker Quantification: Development of an advanced assay to monitor the progress of the disease and the effects of the drug.

4.    Clear Data Integrity, Communication, and Project Management

Close cooperation between the biopharmaceutical sponsor and a CRO scientist is crucial in the preclinical studies. Inefficiencies in data integrity, communication, and project management may easily result in project delays and extra expenses.

The reliable CRO will act as an extended scientific team and provide valuable insights into each milestone of the project:

• Direct Scientists’ Contact: Routine communication with the study directors and principal scientists instead of sales representatives.
• Clear Data Transparency: The use of secure systems for quick data export, visualization, and preliminary results sharing.
• Anticipatory Risk Management: Prompt detection of any unexpected study results with recommendations for further actions.

Transparent data guarantees timely completion of the project and its quick adjustment in case of any unexpected scientific results.

5.    Tailored Study Flexibility and Scalability

Standardized study protocols do not fit modern, complicated drug candidates. Novel approaches, including protein degraders, cell therapies, and bispecific antibodies, need an individualized approach in terms of assay design.

It is important to choose a CRO that will be able to make flexible studies taking into account unique aspects of your molecule:

• Adaptable Study Protocols: Adaptable protocols that are flexible enough depending on preliminary PK results and solubility.
• Adaptable Scope of Studies: Seamless switch between non-GLP exploratory pilot studies and GLP-compliant safety packages.

The adaptable partners ensure that the research team is able to make modifications in the protocols depending on the data collected, thereby avoiding any delay caused by the need to restart the protocol.

Accelerating the Road to Clinical Success

Selecting a CRO for the preclinical research process is an essential step towards ensuring that the candidate progresses quickly through the development phase. Screening of potential partners based on their experience in the therapeutic area, GLP compliance, bioanalytical approach, and open communication ensures you top quality data.

Selection of the best CRO partner enables the drug discovery team to design effective strategies for the clinical trials based on the preclinical data.